Tuesday, August 31, 2021
Investor Ideas #Potcasts 601, #Cannabis News and #Stocks on the Move; (TSX-V: $ENTG.V) (OTCQX: $WDDMF), (TSX: $VLNS.V) (OTCQX: $VLNCF), (TSXV: $KHRN.V) (CSE: $IKNK.U.C)
Investor Ideas #Potcasts 601, #Cannabis News and #Stocks on the Move; (TSX-V: $ENTG.V) (OTCQX: $WDDMF), (TSX: $VLNS.V) (OTCQX: $VLNCF), (TSXV: $KHRN.V) (CSE: $IKNK.U.C)
Delta, Kelowna, BC, August 31, 2021 (Invstorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/083121-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/08311ENTG-WDDMF-VLNS-KHRN-IKNK.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Ikänik Farms, Inc. (CSE: IKNK.U) announced that it has completed the construction and state and local licensing of its Palm Springs dispensary, consumption lounge and home delivery.
"We are very excited to complete our flagship dispensary and consumption lounge that will set a new standard for cannabis experiences in the Palm Springs area, with operations targeted to begin October 2021." said Brian Baca, CEO of Ikänik Farms.
Conveniently located one block from "Main Street" in the heart of Palm Springs, the licensed 1,800 square foot dispensary offers customers an open and modern shopping experience, a highly trained staff, and a wide assortment of California's leading brands and Ikänik products, exclusive brand apparel and other soft goods, locally inspired to create a consumer centric shopping experience. An online reservation system will offer customers the convenience of shopping from their home and will support curbside pickup and home delivery.
The consumption lounge boasts 2,200 square feet of open and airy space, cascaded with natural light from its vaulted ceilings and a state-of-the-art ventilation and filtration system to provide an appealing venue for dispensary customers, private parties, and special events.
The company is excited to provide the Palm Springs area with employment opportunities ranging from store management to budtenders and support staff positions, with well-paying jobs that offer upward mobility and internal promotion opportunities.
"We will see dispensary revenue commence in Q4, with the completion of our California vertical integration supporting margin growth moving into 2022", said Ryan Ciucki, CFO Ikänik Farms.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, announced that it has received sanitary registration in Peru for Alixen™ 30 and Alixen™ 100, two CBD-rich products, which represent the Company's first two registered finished medical cannabis products. As registered medical products, Alixen™ 30 and Alixen™ 100 will be available for distribution through traditional medical channels, including pharmacies, wholesale medical distributors, and dispensaries, greatly expanding product availability while streamlining distribution and prescription delivery.
Currently in Peru, the Company sells magistral preparations, or customized compound formulations, through its exclusive agreement with Farmacia Universal. In contrast, as shelf-ready medical cannabis products, Alixen™ 30™ and Alixen™ 100 will be made widely available, on a non-exclusive basis in the country. Alixen™ 30 will target indications such as anxiety, insomnia, Parkinson's Disease, and depression, while Alixen™ 100 will be used in the treatment of epilepsy. The Company also expects to have finished THC products available for commercial distribution in early 2022 to address additional pathologies, including chronic pain.
In the interim, the Company will continue to fill high-THC magistral preparation prescriptions in partnership with Farmacia Universal and work toward listing the Company's registered medical cannabis products in major national pharmacy chains in Peru.
Alvaro Torres, Khiron CEO and Director, comments, "As we look to establish ourselves as the leading B2C medical cannabis company in Latin America, we are extremely proud to have received our first ever registration of medical cannabis products. Khiron-branded registered medical cannabis products from Colombia will be made available in Peru, providing patients with broader access and quicker prescription delivery through traditional distribution channels. Combined with the recent launch of our first Zerenia™ clinic in Peru, we have the pieces in place to expand in Peru and deliver on our Mission of improving patients' quality of life through medical cannabis."
The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) and Citizen Stash Cannabis Corp. (formerly Experion Holdings Ltd) (TSXV: CSC) (OTCQB: EXPFF) announced that they have entered into an arrangement agreement pursuant to which Valens will acquire all of the issued and outstanding common shares of Citizen Stash by way of a court-approved plan of arrangement under the Canada Business Corporations Act, in an all share transaction. The transaction is valued at approximately $54.3 million on an enterprise value basis.
Under the terms of the Arrangement Agreement, Citizen Stash shareholders will receive 0.1620 of a Valens common share for each Citizen Stash Common Share held. The Exchange Ratio implies a premium per Citizen Stash Common Share of approximately 35.1% based on the 15-day volume-weighted average price of the Citizen Stash Common Shares on the TSX-V and the Valens Shares on the TSX as of the close of markets on August 27, 2021.
The Citizen Stash Acquisition is expected to be accretive to Valens in 2021 and 2022 before synergies, and will provide Valens with strategic, asset-light expansion into flower and pre-rolls, the largest segments of the Canadian cannabis market currently accounting for over 70% of retail sales. This acquisition is anticipated to solidify Valens' position as a top tier cannabis company by enhancing the Company's market share and adding an innovative, premium flower brand to its portfolio. Closing of the Citizen Stash transaction will mark the third acquisition Valens has made this year, which will accelerate Valens' strategic initiative to create a leading global manufacturing platform, capture market share through innovative product launches with unique consumer experiences, and expand on its existing domestic and international distribution network to better capitalize on the global opportunity.
Citizen Stash is a licensed cultivator and processor of premium craft cannabis products based in Mission, British Columbia, and will provide Valens the opportunity to unlock additional growth with its extensive and specialized product portfolio in the premium flower and pre-roll segments. Citizen Stash operates a unique, asset-light platform comprised of a network of craft contract growing partners from which it selectively sources premium bulk flower grown from Citizen Stash's industry leading proprietary genetics. Citizen Stash manufactures and packages flower and pre-roll products primarily through manual processes.
Citizen Stash is one of the top performing premium brands in the flower and pre-roll categories. Based on Hifyre data for the flower category during March to May 2021 in the markets of Ontario, Alberta and British Columbia, Citizen Stash is the highest ranked premium brand by market share in the flower category with an average selling price above $13.00 per gram and is the only brand in the top 20 by market share with an average selling price above $13.00 per gram. Within the pre-roll category during March to May 2021 in the markets of Ontario, Alberta and British Columbia, Citizen Stash is the third highest ranked premium brand with average selling price above $13.00 per gram and one of only five within the top 20 overall brands. The Citizen Stash brand has demonstrated very impressive strength in the competitive flower and pre-roll categories with year-over-year market share gains unlike many other competitor brands – a testament to the product quality and consumer loyalty borne out of Citizen Stash's industry leading genetics.
Tyler Robson, Chief Executive Officer and Chair of the Board of The Valens Company, said, "We are excited to join forces with Citizen Stash's experienced team and broaden our offerings in the flower and pre-roll verticals with a best-in-class brand. The premium price tier of the flower and pre-roll segments represents the best expansion opportunity for Valens in the flower category, as premium brands are the hardest to build, while also capturing the highest margins. Citizen Stash's asset light model, and proprietary genetics will provide us significant operational flexibility and an opportunity to leverage the growing capabilities of our existing LP partners. In short, this strategic acquisition will allow Valens to significantly expand its presence in the recreational market and capture a share of the largest categories of the Canadian cannabis space without the burden of a high-cost growing infrastructure. We are opportunistically expanding our product offering to align with consumer demand for high quality craft cannabis flower and pre-rolls."
Entourage Health Corp. (formerly WeedMD Inc.) (TSX-V:ENTG) (OTCQX:WDDMF), a Canadian producer and distributor of award-winning cannabis products and brands, announced today that its subsidiary and licence holder WeedMD RX Inc. has signed agreements with BBCCC, Inc., a subsidiary of the The Boston Beer Company, Inc. (NYSE: SAM) (‘BBC’), and Ontario-based Peak Processing Solutions (‘Peak’), a subsidiary of Althea Group Holdings Ltd (ASX:AGH), to launch a new portfolio of non-alcoholic cannabis-infused beverages in Canada, with production commencing in Q4, 2021.
Under the terms of the five-year development, supply, manufacturing, sales and marketing agreements, BBC and Peak will develop the beverages with Entourage’s cannabinoid-rich input biomass processed at Peak’s Windsor, Ontario facility. Entourage will be the exclusive distributor of the cannabis-infused beverages in Canada leveraging Entourage’s expansive local sales and marketing network.
“The cannabis market is constantly evolving and with a growing base of consumers seeking consumption alternatives, we’re excited to partner with Boston Beer and Peak to elevate our offerings with Canadian-made, cannabis-infused beverages developed by one of North America’s most iconic craft beer brands,” said George Scorsis, Interim CEO and Executive Chair of Entourage. “We are proud to expand into another consumer vertical with award-winning partners of well-known products that will focus on all segments including the emerging self-care market. Our collective industry expertise coupled with extensive cannabis research and advanced branding strategies will lay the foundation for new product collaborations and further market expansion opportunities at scale. Our strong industry presence, sales force and reputation for consistently delivering award-winning brands in Canada makes this an ideal collaboration.”
Peak Founder and President, Gregg Battersby added: “The team at Peak are delighted to partner with two industry leaders in Entourage Health and The Boston Beer Company to develop what promises to be an exciting range of cannabis-infused beverages. This collaboration is further validation of Peak’s significant and unique capabilities in the Cannabis 2.0 space, and the latest in a growing list of strategic and innovative partnerships.”
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
Friday, August 27, 2021
Investor Ideas #Potcasts 600: #Cannabis News and #Stocks on the Move; (CSE: $BRAX.C) (OTC: $BRAXF) (OTC: $ERBB) (OTCQX: $AVCNF) (NASDAQ: $GNLN)
Investor Ideas #Potcasts 600: #Cannabis News and #Stocks on the Move; (CSE: $BRAX.C) (OTC: $BRAXF) (OTC: $ERBB) (OTCQX: $AVCNF) (NASDAQ: $GNLN)
Delta, Kelowna, BC, August 27, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/082721-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/08271BRAX-ERBB-AVCNF-GNLN.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Greenlane Holdings, Inc. (NASDAQ: GNLN), a global house of brands and one of the largest sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products, announced that its stockholders have approved the proposed merger with KushCo Holdings, Inc., a premier provider of ancillary products and services to the legal cannabis and CBD industries.
Over 99% of the votes cast on the merger proposal were voted in favor of the Transaction. Furthermore, each other proposal submitted to stockholders at Greenlane’s annual meeting of stockholders was approved by the requisite vote. The Company expects to file with the Securities and Exchange Commission a Form 8-K disclosing the final voting results.
Pursuant to the terms of the merger agreement, KushCo will become a wholly owned subsidiary of Greenlane in an all-stock, tax-free business combination. Under the terms of the merger agreement, KushCo’s stockholders will receive shares of Greenlane Class A common stock based on the final exchange ratio to be determined as of the closing date in accordance with the terms of the merger agreement.
Avicanna Inc. (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that, through its majority-owned Colombian subsidiary Santa Marta Golden Hemp S.A.S. (“SMGH”), it has completed its first commercial export of 20 kg of high CBD full spectrum psychoactive cannabis extracts (the “Cannabis Extracts”) to Brazil in connection with the previously announced three (3) year master supply agreement that SMGH executed with a leading Brazilian pharmaceutical in July, 2021.
This marks the 11th country to which Avicanna has successfully completed export of Aureus-branded products in what stands as a demonstration of the Company’s capabilities, innovation, and regulatory expertise. This export also validates the emergence of the global cannabinoid sector with reliance on quality, traceability and sustainability that Avicanna’s Aureus products offer.
With a forecasted total market size of approximately USD $9 billion by 2021, Brazil is expected to be one of the biggest cannabis markets globally and the largest in Latin America, particularly for medicinal cannabis products. The Cannabis Extracts will be used in the production of several products which will be registered and commercialized in Brazil through RDC 327/19 that regulates manufacturing, registration, importation and dispensing of cannabis-derived products.
Lucas Nosiglia, President of Avicanna LATAM, commented: “This export represents a key milestone for our team and a validation of our capabilities as we continue to lead the way with our products and have now entered our 11th country with the Aureus brand. The export to Brazil also confirms the regulatory pathway and acts as a proof of concept in the largest market in South America where we aim to establish long-lasting supply relationships with our Brazilian pharmaceutical partners.”
American Green (OTC: ERBB) announced that it will be expanding its E-commerce presence by launching on Groupon.com. American Green’s premium CBD and Hemp products will be able to be purchased with vouchers located on the Groupon.com platform beginning next month (September 2021). The company is excited to add sales from Groupon as another revenue stream and hopes to echo or exceed the success it is currently enjoying following its launch on Amazon.com.
David G. Gwyther, American Green’s president, said, “We are extremely excited to offer our CBD products on Groupon.com There are very few e-commerce outlets that sell CBD direct to consumers, and Groupon is by far the largest and most successful platform. Groupon has over 24 million customers nationwide. Consumers throughout the country will now have direct access to all of our CBD and Hemp products on Groupon.com.”
“American Green is always looking for innovative ways to introduce its CBD and Hemp products to new prospects and new marketplaces. Groupon is perfectly aligned with our goals with respect to pioneering new ideas that drive rapid growth in e-commerce environments,” said Kevin Davis, VP President of Sales for American Green.
The American Green offers will be optimized and marketed under Groupon's proprietary methods which include but are not limited to: flash sale offers, remarketing campaigns, utilization of additional channels (such as the Groupon app and partner websites) and other online advertising channels.
Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, announced that Braxia Scientific's clinical research and development team will commence a randomized clinical trial (RCT) using psilocybin.
"This will be the broadest study of its kind," said Dr. Joshua Rosenblat, the trial's principal investigator and medical director of the Canadian Rapid Treatment Centre of Excellence Inc. (CRTCE), a wholly owned subsidiary of Braxia Scientific.
"Whereas most other treatment-resistant depression (TRD) studies limit participation to patients that have not found relief from a maximum of five other potential remedies, our research will not have an upper limit, and will even include patients that have endured dozens of unsuccessful medical trials, including ketamine and electroconvulsive therapy.
"By including everyone with more than two failed medical trials, we are increasing the degree to which the results can be applied to a larger population, making our findings much stronger. Furthermore, we will have less exclusion criteria and are even including patients with bipolar depression – a huge first for the field – or comorbid disorders, which were excluded in psilocybin studies done by other companies."
Braxia Scientific CEO Dr. Roger McIntyre added, "Integrating psilocybin provides immense opportunity for benefit for those dealing with treatment-resistant depression. Unfortunately, over one-third of the more than 300 million people suffering with depression worldwide fail to adequately respond to currently approved treatments, and thus the TRD market is very large and disproportionately dominates the majority of mental health services."
The study will demonstrate that the Company can effectively conduct a randomized controlled trial using psychedelic-assisted therapy. This will enable the Company to build the infrastructure for future studies and future clinical care, while also compiling efficacy data and providing the opportunity to evaluate the therapist training program launched at the end of June 2021.
This program run by the Braxia Institute, the Company's training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy, has already cultivated a multi-disciplinary group of 20 therapists from diverse psychiatry and psychotherapy backgrounds to implement safe and effective psilocybin-assisted therapy for patients with depression.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
New #Stocks to Watch at Investor Ideas in Biotech (NasdaqGS: $IPSC) (NYSE: $AMAM), (NasdaqGS: $CYT) and Cannabis (CSE: $POKO.C), (CSE: $RIV.C)
New #Stocks to Watch at Investor Ideas in Biotech (NasdaqGS: $IPSC) (NYSE: $AMAM), (NasdaqGS: $CYT) and Cannabis (CSE: $POKO.C), (CSE: $RIV.C)
Also new stocks in Mining, Cleantech and Psychedelics
Point Roberts WA, Delta BC, August 27, 2021 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, cannabis, mining, cleantech and psychedelics. Today’s stocks have been added to our lists of free stock directories in each sector.
Read this in full at https://www.investorideas.com/news/2021/main/08271Stocks.asp
The newest biotechnology companies are involved in biotech, biopharma and biomedical along with life sciences and healthcare technology.
The latest cannabis companies include both a CBD and a cannabis focused company.
The newest mining companies are both Canadian-listed, as is the latest cleantech company.
The newest psychedelics company is involved in the use of ketamine-enhanced products for psychotherapy.
New Stocks added to Biotech Stocks Directory:
FEMASYS INC (NasdaqCM:FEMY) is a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies. Its two lead reproductive health product candidates include FemBloc® permanent birth control and FemaSeed™ localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.
Codex DNA, Inc. (NasdaqGS:DNAY) is empowering scientists with the ability to address many of humanity’s greatest challenges through synthetic biology. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm to create novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego.
Alzamend Neuro, Inc. (NasdaqCM:ALZN) is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic crystal-engineered combination of lithium, proline and salicylate, and AL002 – a patented therapeutic mutant-peptide sensitized cell-based therapeutic vaccine that is targeted to augment the ability of a patient’s immune system to combat Alzheimer’s disease. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
MOLECULAR PARTNERS AG (NasdaqGS:MOLN) is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Lyell Immunopharma, Inc. (NasdaqGS:LYEL) is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses to adoptive T cell therapy: T cell exhaustion and lack of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, California and Seattle and Bothell, Washington.
Unicycive Therapeutics, Inc. (NasdaqCM:UNCY) is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
Cyteir Therapeutics, Inc. (NasdaqGS:CYT) is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
Ambrx Biopharma Inc. (NYSE:AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
Century Therapeutics, Inc. (NasdaqGS:IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care.
iSpecimen Inc. (NasdaqCM:ISPC) offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.
SpotLite360 IOT Solutions, Inc. (CSE:LITE) is a supply chain and healthcare company focused on the delivery of a SaaS-based supply chain execution and sustainability platform (SpotLite 360 Software) for enterprise customers in the pharmaceutical, healthcare, and agricultural industries. By leveraging IoT technologies, blockchain, machine learning and analytics, the Spotlite360 Software is uniquely positioned to meet customer needs for supply chain execution, tracing, tracking, and sustainability. Future customers of the Spotlite360 Software will benefit by realizing improved visibility, a reduction in loss and theft, increased supply chain velocity, labor efficiency, improves asset utilization, and support of their global sustainability initiatives.
New stocks added to Cannabis Stocks Directory:
RIV Capital Inc. (CSE: RIV) is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies.
Poko Innovations Inc. (CSE: POKO) Formerly Brunswick Resources Inc.- is an award winning European-based company that leverages its strong portfolio of CBD brands, including financial services platform Lumipay, news and media sites, The Extract and Candid Magazine and consumer brands Poko and Canndid. These brands form a complete ecosystem that brings innovative solutions to the CBD industry-from supplying businesses with high-quality CBD-derived products and other natural health supplements to offering a reliable payment gateway service for high-risk industries and providing a CBD-focused marketplace for buyers and sellers to connect and trade. The Company has leadership teams located in Ireland, United Kingdom, Canada and the United States.
New stocks added to Mining Stocks Directory:
1111 Exploration Corp. (CSE:ELVN) is a junior exploration company, focused on creating shareholder value through acquisition, exploration and development of mineral projects.
Fokus Mining Corporation (TSXV:FKM) is a mineral resource company actively acquiring and exploring precious metal deposits located in the province of Quebec, Canada. In implementing this major undertaking within the Canadian mining industry, we are determined to unlock the secret of the Galloway gold project. The Galloway project covers an area of 2,865.54 hectares and is located just north of the Cadillac-Larder Lake deformation which extends laterally for more than 100 km. Numerous gold deposits are related to that structure and its subsidiaries. The current work focuses on a small western portion of the mineral claims where several mineral occurrences have been identified
New stocks added to Cleantech Stocks Directory:
Delta Cleantech Inc. (CSE: DELT) provides clean energy engineering services and technology in response to issues around environmental, social and corporate governance (ESG) and identity preserved waste. Delta CleanTech is a technology industry leader in CO2 Capture; Solvent & Glycol Reclamation and Hydrogen Fueling Infrastructure
New stocks added to Psychedelics Stocks Directory:
Revitalist Lifestyle and Wellness Ltd. (CSE:CALM) provides patient-focused treatments for mental health and pain disorders through the operation of psychedelic-enhanced psychotherapy clinics, which guide patients through ketamine-enhanced psychotherapy. Revivalist commenced operations in 2018 at is existing location in Knoxville Tennessee and is working on a rapid expansion in the United States. Revivalist seeks to create a global brand of psychedelic-enhanced psychotherapy clinics for ketamine-enhanced psychotherapy, psychedelic-enhanced psychotherapy, ketamine infusion therapy, vitamin infusions, and transcranial magnetic stimulation focusing on mental health and pain disorders
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research, guest posts and original articles and podcasts in leading stock sectors. Learn about investing in stocks and get investor ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s original branded content includes podcasts and columns : Crypto Corner , Play by Play sports and stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye Podcast.
Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea's original branded content includes the following podcasts and columns: Crypto Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the sectors we cover use our news and content services to tell their story to interested investors. Paid for content is disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Subscribe to:
Posts (Atom)